Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a Hold rating on Integra Lifesciences (IART) and lowers the price target from $37 to $25.
May 07, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Truist Securities maintains a Hold rating on Integra Lifesciences and reduces the price target from $37 to $25.
The reduction in price target by Truist Securities suggests a bearish outlook on the stock's short-term price potential, likely due to revised expectations on the company's future performance. This could lead to negative investor sentiment and a potential decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100